VMD-928
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 82 patients (estimated)
- Sponsors
- VM Oncology, LLC
- Tags
- Tyrosine Kinase (TK) Inhibitor
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1401
- NCT Identifier
- NCT03556228
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.